Subscribe To

Price Alert Latest News Economic Calendar News

PLRX / Pliant Therapeutics shares rally 75%

Shares of Pliant Therapeutics Inc. PLRX, +2.62% soared about 75% in premarket trading on Monday, the day after the company said a high dose of its experimental treatment for idiopathic pulmonary fibrosis met the primary and secondary endpoints in a Phase 2a clinical trial. Pliant, which is testing four different doses of bexotegrast, said 21 patients received the 320 milligram dose — the highest dose — and will continue to receive treatment for 24 weeks. Read More

Demo Live Account See Partner Details

Content Topics

Pliant

Therapeutics

Rally

Stock

PLRX

Posted: Jan 23 2023, 07:49

Author Name: Market Watch

PLRX News

By Zacks Investment Research
September 27, 2023

Pliant (PLRX) Up on Success of Mid-Stage Liver Disease Study

Shares of Pliant Therapeutics, Inc. PLRX gained 14.3% on Sep 26 after the company announced that its mid-stage study on lead pipeline candidate bexote

By The Motley Fool
September 26, 2023

Why Shares of Pliant Therapeutics Are Rising Tuesday

Pliant Therapeutics is a clinical-stage biotech. The company said it has enough cash to fund operations through the second half of 2026.

By Market Watch
September 26, 2023

Pliant Therapeutics shares surge as liver-disease treatment shows promise in clinical trial

Pliant Therapeutics Inc. shares PLRX, -2.86% gained 23% premarket on Tuesday after the company released results from a trial of bexotegrast, a treatme

By Seeking Alpha
August 11, 2023

Pliant Therapeutics: Promising Phase 2a Bexotegrast Data Unveiled

Pliant Therapeutics is a biotech company focused on developing therapies for fibrotic diseases. The company's financials show an increase in R&D and a

By Zacks Investment Research
August 9, 2023

Pliant Therapeutics, Inc. (PLRX) Reports Q2 Loss, Misses Revenue Estimates

Pliant Therapeutics, Inc. (PLRX) came out with a quarterly loss of $0.70 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compar

By Zacks Investment Research
May 9, 2023

Pliant Therapeutics, Inc. (PLRX) Reports Q1 Loss, Misses Revenue Estimates

Pliant Therapeutics, Inc. (PLRX) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compar

By Seeking Alpha
April 15, 2023

Pliant Therapeutics: A Breath Of Fresh Air For A Multibillion Dollar IPF Market

By Zacks Investment Research
March 9, 2023

Pliant Therapeutics, Inc. (PLRX) Reports Q4 Loss, Tops Revenue Estimates

Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of -2.86% and 27.10%, respectively, for the quarter ended December 2022. Do

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.